{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:37:38Z","timestamp":1789623458994,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373183"],"award-info":[{"award-number":["82373183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtct.2026.05.019","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T07:04:54Z","timestamp":1779174294000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Next-Generation CAR-T Therapies: From Personalized Anticancer Drugs to Broadly Applicable Disease-Modifying Treatments"],"prefix":"10.1016","author":[{"given":"Mengru","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.05.019_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.trecan.2025.08.014","article-title":"CAR T cell persistence in cancer","author":"Mueller","year":"2025","journal-title":"Trends Cancer"},{"issue":"7949","key":"10.1016\/j.jtct.2026.05.019_bib0002","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"issue":"6382","key":"10.1016\/j.jtct.2026.05.019_bib0003","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtct.2026.05.019_bib0004","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","author":"Li","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtct.2026.05.019_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.744823","article-title":"Advances in universal CAR-T cell therapy","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.019_bib0006","article-title":"HLA molecules: another challenge for CAR T cell therapy","volume":"73","author":"Salih","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.jtct.2026.05.019_bib0007","article-title":"Allogeneic \u201coff-the-shelf\u201d CAR T cells: challenges and advances","author":"Chen","year":"2024","journal-title":"Best Pr"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.019_bib0008","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.05.019_bib0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canlet.2019.01.017","article-title":"CRISPR-Cas9 for cancer therapy: opportunities and challenges","volume":"447","author":"Chen","year":"2019","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.019_bib0010","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.019_bib0011","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0012","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1182\/blood-2024-204401","article-title":"A first-in-human study of CT0590, a triple knock-out, allogeneic CAR T-cell therapy targeting BCMA and NKG2A, in subjects with relapsed\/refractory multiple myeloma","volume":"144","author":"Fu","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0013","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2024-203563","article-title":"CTX112, a next-generation allogeneic CRISPR-Cas9 engineered CD19 CAR T cell with novel potency edits: data from phase 1 dose escalation study in patients with relapsed or refractory B-cell malignancies","volume":"144","author":"Ghobadi","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.019_bib0014","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0015","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2021-146045","article-title":"ALPHA2 study: ALLO-501A allogeneic CAR T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing","volume":"138","author":"Lekakis","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2026.05.019_bib0016","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2023.41.16_suppl.2517","article-title":"Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501\/501A in relapsed\/refractory large B-cell lymphoma (r\/r LBCL)","volume":"41","author":"Locke","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.05.019_bib0017","unstructured":"Srour SA, Chahoud J, Drakaki A, et al. ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): updated results from the phase 1 TRAVERSE study."},{"issue":"4","key":"10.1016\/j.jtct.2026.05.019_bib0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","article-title":"High-specificity CRISPR-mediated genome engineering in anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models","volume":"12","author":"Degagn\u00e9","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.019_bib0019","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0020","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1182\/blood-2023-182430","article-title":"Early safety results of P-BCMA-ALLO1, a fully allogeneic chimeric antigen receptor T-cell (CAR-T), in patients with relapsed \/refractory multiple myeloma (RRMM)","volume":"142","author":"Dholaria","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0021","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1182\/blood-2024-207459","article-title":"A phase 1 study of P-BCMA-ALLO1, a non-viral, allogeneic BCMA directed CAR-T in relapsed\/refractory multiple myeloma (RRMM): results from optimized lymphodepletion cohort","volume":"144","author":"Dholaria","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.019_bib0022","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.019_bib0023","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","article-title":"Fratricide-resistant CD7-CAR T cells in T-ALL","volume":"30","author":"Oh","year":"2024","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.jtct.2026.05.019_bib0024","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtct.2026.05.019_bib0026","unstructured":"Neelapu SS, Hamadani M, Miklos DB, et al. A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u0393\u03b4) T cells in adults with B-cell malignancies."},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u0393\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.019_bib0028","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13238-017-0411-9","article-title":"Increasing the safety and efficacy of chimeric antigen receptor T cell therapy","volume":"8","author":"Li","year":"2017","journal-title":"Protein Cell"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0029","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0031","article-title":"Perspectives on the use and availability of chimeric antigen receptor T cells (CAR-T) and cell therapies: a worldwide cross-Sectional survey by the worldwide network for blood and marrow transplantation (WBMT)","volume":"73","author":"Tan","year":"2025","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0032","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","article-title":"Recent advances in universal chimeric antigen receptor T cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.019_bib0033","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/ijms26073119","article-title":"Vivo engineered CAR-T cell therapy: lessons built from COVID-19 mRNA vaccines","volume":"26","author":"Meng","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2026.05.019_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.019_bib0035","article-title":"Vivo production of CAR T cell: opportunities and challenges","volume":"12","author":"Song","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.jtct.2026.05.019_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2026.05.019_bib0037","unstructured":"Hunter TL, Zhang Y, Matsuda D, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease."},{"key":"10.1016\/j.jtct.2026.05.019_bib0038","unstructured":"Frank AM, Braun AH, Scheib L, et al. Combining T-Cell\u2013Specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors."},{"issue":"17","key":"10.1016\/j.jtct.2026.05.019_bib0039","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.3390\/ijms26178497","article-title":"Lentiviral vectors: from wild-type viruses to efficient multi-functional delivery vectors","volume":"26","author":"Arrasate","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.019_bib0040","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.ymthe.2025.07.006","article-title":"Efficient in vivo generation of CAR T cells using a retargeted fourth-generation lentiviral vector","volume":"33","author":"Coradin","year":"2025","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.019_bib0041","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.05.019_bib0042","unstructured":"A phase 1 study to evaluate the safety of KLN\u20111010, a novel."},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0043","doi-asserted-by":"crossref","first-page":"1750.1","DOI":"10.1182\/blood-2024-208461","article-title":"A phase 1, multicenter, open-label study of UB-VV111 in combination with rapamycin in relapsed\/refractory CD19+ B-cell malignancies","volume":"144","author":"Garcia","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.019_bib0044","series-title":"Regular and Young Investigator Award Abstracts","first-page":"A1267","article-title":"1145 development of a surface engineered lentiviral vector for in vivo generation of CD22-directed CAR T cells","author":"Teoh","year":"2024"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.019_bib0045","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.019_bib0046","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.05.019_bib0047","series-title":"Regular and Young Investigator Award Abstracts","first-page":"A1327","article-title":"1203 targeted in vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform","author":"Andorko","year":"2023"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.019_bib0048","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1016\/j.ymthe.2025.03.018","article-title":"CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery","volume":"33","author":"Papp","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.05.019_bib0049","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.10.061","article-title":"Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery","volume":"352","author":"Wang","year":"2022","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0050","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12967-025-06435-0","article-title":"Nanocarriers for cutting-edge cancer immunotherapies","volume":"23","author":"Hu","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.jtct.2026.05.019_bib0051","unstructured":"Myeloid therapeutics initiates patient dosing with MT-302, a novel."},{"key":"10.1016\/j.jtct.2026.05.019_bib0052","unstructured":"Lemech CR, Cosman R, Humphries TG, et al. First-in-human mRNA CAR therapy: correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors."},{"key":"10.1016\/j.jtct.2026.05.019_bib0053","unstructured":"Humphries TG, Roberts SK, Sim H-W, et al. A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma."},{"key":"10.1016\/j.jtct.2026.05.019_bib0054","unstructured":"Myeloid therapeutics initiates patient dosing with MT-303, a novel GPC3."},{"key":"10.1016\/j.jtct.2026.05.019_bib0055","unstructured":"Du Y, Wu J, Hu C, et al. A Phase I\/IIa study to evaluate the tolerability, safety, pharmacokinetics and efficacy of eciruciclib (BPI-1178) alone in advanced solid tumors and in combination with endocrine therapy for advanced or recurrent HR+\/HER2- breast cancer."},{"issue":"7","key":"10.1016\/j.jtct.2026.05.019_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"Cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.019_bib0057","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Intern Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.019_bib0058","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0059","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","article-title":"T cells in health and disease","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"10416","key":"10.1016\/j.jtct.2026.05.019_bib0060","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.jtct.2026.05.019_bib0061","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"8034","key":"10.1016\/j.jtct.2026.05.019_bib0062","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/d41586-024-03209-4","article-title":"World-first therapy using donor cells sends autoimmune diseases into remission","volume":"634","author":"Mallapaty","year":"2024","journal-title":"Nature"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.05.019_bib0063","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood-2020-142423","article-title":"A phase I study of FT819, a first-of-kind, off-the-shelf, iPSC-derived TCR-less CD19 CAR T cell therapy for the treatment of relapsed\/refractory B-cell malignancies","volume":"136","author":"Park","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.05.019_bib0064","unstructured":"Neelapu SS, Hamadani M, Miklos DB, et al. A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma delta (\u0393\u03b4) T cells in adults with B-cell malignancies."},{"issue":"6576","key":"10.1016\/j.jtct.2026.05.019_bib0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jtct.2026.05.019_bib0066","unstructured":"Hunter TL, Soldevila F, Zhang Y, et al. A novel product candidate (CPTX2309) for in vivo mRNA engineering of anti-CD19 CAR T cells utilizing novel CD8-targeted lipid nanoparticles."},{"key":"10.1016\/j.jtct.2026.05.019_bib0067","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.019_bib0068","doi-asserted-by":"crossref","DOI":"10.1101\/2024.11.21.624667","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in-vivo CAR-T therapy for inflamm-aging","author":"Zhang","year":"2024","journal-title":"Bioengineering"},{"issue":"5","key":"10.1016\/j.jtct.2026.05.019_bib0069","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/j.ymthe.2025.03.005","article-title":"From concept to cure: the evolution of CAR-T cell therapy","volume":"33","author":"Patel","year":"2025","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","article-title":"Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study","volume":"10","author":"Mao","year":"2024","journal-title":"Cell Discov"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.019_bib0071","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.019_bib0072","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41375-019-0610-x","article-title":"HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation","volume":"34","author":"Jin","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.019_bib0073","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0074","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13046-019-1153-8","article-title":"Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment","volume":"38","author":"Looi","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jtct.2026.05.019_bib0076","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene Therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0077","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","article-title":"Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies","volume":"11","author":"Dabiri","year":"2023","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0078","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20230036","article-title":"mRNA-based chimeric antigen receptor T cell therapy: basic principles, recent advances and future directions","volume":"2","author":"Xiao","year":"2024","journal-title":"Interdiscip Med"},{"issue":"14","key":"10.1016\/j.jtct.2026.05.019_bib0079","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMoa2400442","article-title":"Lentiviral gene therapy for cerebral adrenoleukodystrophy","volume":"391","author":"Eichler","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.019_bib0080","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo car gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.05.019_bib0081","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jtct.2026.05.019_bib0082","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.019_bib0083","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.05.019_bib0084","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"Npj Vaccines"},{"issue":"7","key":"10.1016\/j.jtct.2026.05.019_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103610","article-title":"Treatment to cure: advancing AAV gene therapy manufacture","volume":"28","author":"Young","year":"2023","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jtct.2026.05.019_bib0087","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV capsid to evade immune responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0088","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkae1213","article-title":"Precision genome editing using combinatorial viral vector delivery of CRISPR-Cas9 nucleases and donor DNA constructs","volume":"53","author":"Li","year":"2025","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.019_bib0089","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.ymthe.2024.09.019","article-title":"Synergistic integration of mRNA-LNP with CAR-engineered immune cells: pioneering progress in immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat Protoc"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0091","doi-asserted-by":"crossref","first-page":"5659","DOI":"10.1038\/s41467-024-50093-7","article-title":"Reformulating lipid nanoparticles for organ-targeted mRNA accumulation and translation","volume":"15","author":"Su","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtct.2026.05.019_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114861","article-title":"Lipid nanoparticle-mediated drug delivery to the brain","volume":"197","author":"Khare","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jtct.2026.05.019_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116028","article-title":"Recent progress and challenges for polymeric microsphere compared to nanosphere drug release systems: is there a real difference?","volume":"33","author":"Alavi","year":"2021","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.019_bib0094","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3390\/molecules27092902","article-title":"Hydrogels: properties and applications in biomedicine","volume":"27","author":"Ho","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jtct.2026.05.019_bib0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","article-title":"Polymeric micelles in cancer therapy: state of the art","volume":"332","author":"Ghosh","year":"2021","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0096","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41573-023-00827-x","article-title":"The art of therapeutic mRNA design","volume":"23","author":"Metkar","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0097","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/pathogens12010138","article-title":"Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development","volume":"12","author":"Schmidt","year":"2023","journal-title":"Pathogens"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.019_bib0098","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3390\/v16040503","article-title":"Trans-amplifying RNA: a journey from alphavirus research to future vaccines","volume":"16","author":"Y\u0131ld\u0131z","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.jtct.2026.05.019_bib0099","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.jtct.2026.05.019_bib0100","article-title":"Sacituzumab tirumotecan in EGFR-TKI\u2013resistant, EGFR -mutated advanced NSCLC","author":"Fang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.05.019_bib0101","unstructured":"Steffin D Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers."},{"issue":"6","key":"10.1016\/j.jtct.2026.05.019_bib0102","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0103","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/s12967-024-05462-7","article-title":"Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer","volume":"22","author":"Deng","year":"2024","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.019_bib0104","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41565-025-01924-1","article-title":"A collagenase nanogel backpack improves CAR-T cell therapy outcomes in pancreatic cancer","volume":"20","author":"Zhao","year":"2025","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202407425","article-title":"Photo-metallo-immunotherapy: fabricating chromium-based nanocomposites to enhance CAR-T cell infiltration and cytotoxicity against solid tumors","volume":"37","author":"Zou","year":"2025","journal-title":"Adv Mater"},{"issue":"9","key":"10.1016\/j.jtct.2026.05.019_bib0106","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.immuni.2025.07.018","article-title":"Mechanical signaling via \u03922 integrin decouples T cell proliferation and differentiation for generating stem cell-like CAR T cells","volume":"58","author":"Lv","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2026.05.019_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0108","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1186\/s40425-019-0804-9","article-title":"Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity","volume":"7","author":"Torres Chavez","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.jtct.2026.05.019_bib0109","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s13238-019-0643-y","article-title":"Chimeric antigen receptor T (CAR-T) cells expanded with IL-7\/IL-15 mediate superior antitumor effects","volume":"10","author":"Zhou","year":"2019","journal-title":"Protein Cell"},{"key":"10.1016\/j.jtct.2026.05.019_bib0110","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3389\/fimmu.2017.01221","article-title":"PI3K\u03b4 inhibition enhances the antitumor fitness of adoptively transferred CD8+ T cells","volume":"8","author":"Bowers","year":"2017","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0111","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-Cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0112","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.tips.2020.11.004","article-title":"Innate and innate-like cells: the future of chimeric antigen receptor (CAR) cell therapy","volume":"42","author":"Cort\u00e9s-Selva","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0114","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","article-title":"Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2026.05.019_bib0115","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.jtct.2026.05.019_bib0116","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0117","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.05.019_bib0118","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0119","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","article-title":"Targeting triple-negative breast cancer using cord-blood CD34+ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity","volume":"18","author":"Li","year":"2025","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.05.019_bib0120","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jtct.2026.05.019_bib0121","article-title":"IL23R-specific CAR Tregs for the treatment of Crohn\u2019s disease","author":"Cui","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jtct.2026.05.019_bib0122","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","article-title":"Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of Asthma","volume":"8","author":"Skuljec","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jtct.2026.05.019_bib0123","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-Treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:12:16Z","timestamp":1783102336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":123,"alternative-id":["S2666636726003623"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-Generation CAR-T Therapies: From Personalized Anticancer Drugs to Broadly Applicable Disease-Modifying Treatments","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}